Reflection Asset Management Acquires New Stake in Henry Schein, Inc. $HSIC

Reflection Asset Management bought a new position in shares of Henry Schein, Inc. (NASDAQ:HSIC) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 6,833 shares of the company’s stock, valued at approximately $516,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. CYBER HORNET ETFs LLC purchased a new stake in Henry Schein during the second quarter worth about $25,000. MUFG Securities EMEA plc purchased a new position in shares of Henry Schein in the second quarter valued at approximately $27,000. Flagship Harbor Advisors LLC purchased a new position in shares of Henry Schein in the fourth quarter valued at approximately $30,000. Federated Hermes Inc. acquired a new position in shares of Henry Schein in the fourth quarter valued at approximately $32,000. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Henry Schein in the fourth quarter valued at approximately $37,000. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HSIC has been the topic of a number of research reports. Barrington Research set a $97.00 target price on shares of Henry Schein and gave the stock an “outperform” rating in a report on Wednesday, February 25th. UBS Group reaffirmed a “neutral” rating and set a $85.00 price objective (down from $87.00) on shares of Henry Schein in a research report on Wednesday, May 6th. JPMorgan Chase & Co. increased their price objective on Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Citigroup started coverage on Henry Schein in a report on Wednesday, April 15th. They issued a “buy” rating and a $100.00 target price for the company. Finally, BTIG Research raised Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Thursday, June 11th. Seven equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $87.85.

Henry Schein Price Performance

Shares of Henry Schein stock opened at $79.92 on Friday. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. Henry Schein, Inc. has a 52-week low of $61.94 and a 52-week high of $89.29. The company has a market capitalization of $9.10 billion, a P/E ratio of 24.15, a P/E/G ratio of 1.54 and a beta of 0.82. The company has a 50 day moving average of $75.96 and a 200 day moving average of $76.40.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The company had revenue of $3.37 billion for the quarter, compared to the consensus estimate of $3.34 billion. During the same period in the prior year, the firm posted $1.15 EPS. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, research analysts forecast that Henry Schein, Inc. will post 5.32 EPS for the current fiscal year.

Insider Activity at Henry Schein

In other news, Director William K. Daniel bought 10,000 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $69.19 per share, for a total transaction of $691,900.00. Following the completion of the purchase, the director owned 20,000 shares in the company, valued at approximately $1,383,800. This trade represents a 100.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.89% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.